Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Sales (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Return on Sales data on record, last reported at 84.7% in Q3 2025.

  • For Q3 2025, Return on Sales fell 3742.0% year-over-year to 84.7%; the TTM value through Sep 2025 reached 78.38%, down 3473.0%, while the annual FY2024 figure was 53.74%, 2230.0% down from the prior year.
  • Return on Sales reached 84.7% in Q3 2025 per NWBO's latest filing, up from 126.76% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.9% in Q1 2023 and bottomed at 126.76% in Q2 2025.
  • Average Return on Sales over 5 years is 55.48%, with a median of 47.23% recorded in 2022.
  • Peak YoY movement for Return on Sales: skyrocketed 5273bps in 2022, then tumbled -8922bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 34.06% in 2021, then grew by 5bps to 32.49% in 2022, then fell by -13bps to 36.82% in 2023, then tumbled by -147bps to 90.85% in 2024, then increased by 7bps to 84.7% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 84.7% in Q3 2025, 126.76% in Q2 2025, and 50.43% in Q1 2025.